GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NeuroOne Medical Technologies Corp (NAS:NMTC) » Definitions » Cash Flow from Investing

NeuroOne Medical Technologies (NeuroOne Medical Technologies) Cash Flow from Investing : $0.74 Mil (TTM As of Mar. 2024)


View and export this data going back to 2012. Start your Free Trial

What is NeuroOne Medical Technologies Cash Flow from Investing?

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in Mar. 2024, NeuroOne Medical Technologies spent $0.03 Mil on purchasing property, plant, equipment. It gained $0.00 Mil from selling property, plant, and equipment. It spent $0.00 Mil on purchasing business. It gained $0.00 Mil from selling business. It spent $0.00 Mil on purchasing investments. It gained $0.00 Mil from selling investments. It paid $0.00Mil for net Intangibles purchase and sale. And it paid $0.00 Mil for other investing activities. In all, NeuroOne Medical Technologies spent $0.03 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Mar. 2024.


NeuroOne Medical Technologies Cash Flow from Investing Historical Data

The historical data trend for NeuroOne Medical Technologies's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NeuroOne Medical Technologies Cash Flow from Investing Chart

NeuroOne Medical Technologies Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Cash Flow from Investing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.12 -0.12 -0.07 -3.25 2.65

NeuroOne Medical Technologies Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.82 0.86 -0.05 -0.04 -0.03

NeuroOne Medical Technologies Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

NeuroOne Medical Technologies's Cash Flow from Investing for the fiscal year that ended in Sep. 2023 is calculated as:

NeuroOne Medical Technologies's Cash Flow from Investing for the quarter that ended in Mar. 2024 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.74 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NeuroOne Medical Technologies  (NAS:NMTC) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

NeuroOne Medical Technologies's purchase of property, plant, equipment for the three months ended in Mar. 2024 was $-0.03 Mil. It means NeuroOne Medical Technologies spent $0.03 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

NeuroOne Medical Technologies's sale of property, plant, equipment for the three months ended in Mar. 2024 was $0.00 Mil. It means NeuroOne Medical Technologies gained $0.00 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

NeuroOne Medical Technologies's purchase of business for the three months ended in Mar. 2024 was $0.00 Mil. It means NeuroOne Medical Technologies spent $0.00 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

NeuroOne Medical Technologies's sale of business for the three months ended in Mar. 2024 was $0.00 Mil. It means NeuroOne Medical Technologies gained $0.00 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

NeuroOne Medical Technologies's purchase of investment for the three months ended in Mar. 2024 was $0.00 Mil. It means NeuroOne Medical Technologies spent {stock_data.stock.currency_symbol}}0.00 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

NeuroOne Medical Technologies's sale of investment for the three months ended in Mar. 2024 was $0.00 Mil. It means NeuroOne Medical Technologies gained $0.00 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

NeuroOne Medical Technologies's net Intangibles purchase and sale for the three months ended in Mar. 2024 was $0.00 Mil. It means NeuroOne Medical Technologies paid $0.00 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

NeuroOne Medical Technologies's cash from discontinued investing activities for the three months ended in Mar. 2024 was 0.00 Mil. It means NeuroOne Medical Technologies paid $0.00 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

NeuroOne Medical Technologies's cash from other investing activities for the three months ended in Mar. 2024 was $0.00 Mil. It means NeuroOne Medical Technologies paid $0.00 Mil for other investing activities.


NeuroOne Medical Technologies Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of NeuroOne Medical Technologies's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


NeuroOne Medical Technologies (NeuroOne Medical Technologies) Business Description

Traded in Other Exchanges
N/A
Address
7599 Anagram Dr., Eden Prairie, MN, USA, 55344
NeuroOne Medical Technologies Corp operates as a medical technology company. It is focused on the development and commercialization of thin-film electrode technology for continuous electroencephalogram (cEEG) and stereoelectrocencephalography (sEEG) recording, brain stimulation, and ablation solutions for patients suffering from brain-related disorders. The company business is in one operating segment, which is the business of development and commercialization of products related to comprehensive neuromodulation cEEG and sEEG recording, monitoring, ablation, and brain stimulation solutions.
Executives
Mark Christianson 10 percent owner, officer: VP, Business Dev and Marketing 10006 LIATRIS LANE, EDEN PRAIRIE MN 55347
Ronald W. Mcclurg officer: Chief Financial Officer C/O NEUROONE MEDICAL TECHNOLOGIES CORP, 7599 ANAGRAM DR, EDEN PRAIRIE MN 55344
David A Rosa director, officer: CEO and President 10901 RED CIRCLE DRIVE, SUITE 150, MINNETONKA MN 55343
Hijaz Haris officer: VP of Marketing C/O NEUROONE MEDICAL TECHNOLOGIES CORP, 7599 ANAGRAM DR, EDEN PRAIRIE MN 55344
Morgan C. Frank 10 percent owner 2 CALLE NAIRN, UNIT 701, SAN JUAN PR 00907
Manchester Management Co Llc 10 percent owner 3 WEST HILL PLACE, BOSTON MA 02110
Manchester Explorer, L.p. 10 percent owner MANCHESTER MANAGEMENT COMPANY, L.L.C, 3 WEST HILL PLACE, Boston ma 02114
James E Besser 10 percent owner 3 WEST HILL PLACE, BOSTON MA 02114
Manchester Management Pr, Llc 10 percent owner 3 WEST HILL PLACE, BOSTON MA 02114
Edward Andrle director C/O NEUROONE MEDICAL TECHNOLOGIES CORP, 7599 ANAGRAM DRIVE, EDEN PRAIRIE MN 55344
Wade Fredrickson 10 percent owner 10006 LIATRIS LANE, EDEN PRAIRIE MN 55347
Steve Mertens officer: Chief Technology Officer 10901 RED CIRCLE DR., SUITE 150, MINNETONKA MN 55343
Scott Heuler officer: Vice President of Sales 10901 RED CIRCLE DR., SUITE 150, MINNETONKA MN 55343
Paul Buckman director 12988 VALLEY VIEW RD, EDEN PRAIRIE MN 55402
Suraj Kalia director 10006 LIATRIS LANE, EDEN PRAIRIE MN 55347